智通财经APP获悉，归创通桥(02190)盘中涨超5%，截至发稿，涨3.76%，报23.2港元，成交额1539.07万港元。
消息面上，本月初，归创通桥旗下归创医疗自主研发的ZYLOX KINGKONG 金刚™外周高压球囊扩张导管经过国家药品监督管理局审查批准，正式获批上市。该产品适用于包括上肢、肾、髂和腹股沟下血管在内的周围血管的经皮腔内血管成形术，以及治疗自体或人造透析用动静脉痿的狭窄，也适用于外周血管系统中的支架和覆膜支架的后扩张。
中信建投此前指出，公司是国内外周介入和神经介入行业的龙头企业，产品管线丰富，更有多款创新产品有望陆续获批，在部分产品有望受益集采、进口替代加速的背景下，公司内生业务有望保持快速增长。2024年公司首次实现扭亏为盈，随着公司销售规模的持续扩大，叠加公司管理经营效率的持续改善，公司盈利能力有望持续提升。公司在手资金充裕，截至25H1，公司在手现金为25.3 亿元，预计公司将继续加大产品研发和学术推广力度，并寻求外延并购及对外合作的机会，不断稳固公司行业龙头的地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.